福元医药(601089.SH)：坎地沙坦酯氢氯噻嗪片（Ⅱ）获得药品注册证书

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) has received the drug registration certificate from the National Medical Products Administration for Candesartan Cilexetil and Hydrochlorothiazide Tablets, indicating a significant regulatory approval for the company’s product line [1] Group 1: Product Approval - The company has been granted a drug registration certificate for Candesartan Cilexetil and Hydrochlorothiazide Tablets, with a specification of 16mg of Candesartan Cilexetil and 12.5mg of Hydrochlorothiazide per tablet [1] - This medication is not intended for initial treatment of hypertension but is suitable for adults with primary hypertension whose blood pressure is not effectively controlled by either Candesartan Cilexetil or Hydrochlorothiazide alone, or as a replacement therapy at the same dosage for the combination of both drugs [1]